BACKGROUND: There are a few studies on the treatment of sporotrichosis. The standard drug used is itraconazole. However, the use of itraconazole is limited by its interaction with other drugs. OBJECTIVE: To evaluate the effectiveness and safety of 250 mg terbinafine for the treatment of cutaneous sporotrichosis in patients in whom itraconazole use is not possible. METHODS: We performed a descriptive study of cutaneous sporotrichosis cases treated with 250 mg terbinafine for which itraconazole was contraindicated or resulted in severe or moderate pharmacological interactions. Sporotrichosis was diagnosed based on the isolation of S. schenckii. RESULTS: Fifty patients seen between July 2005 and September 2007 were included. Forty-five (92%) patients reported contact with a sick cat and 47 (94%) presented comorbidities (high blood pressure: 64.0%; diabetes mellitus: 30.0%; dyslipidemia: 16.7%; depression: 10.0%; migraine: 2.1%; Parkinsonís disease: 2.1%; peptic ulcer disease: 2.1%; heart failure: 2.1%, and arrhythmia: 2.1%). All patients used some medication interacting with itraconazole (psycholeptics: 36.0%; antidiabetic agents: 28.0%; hypolipemiant agents: 18.0%; calcium-channel blockers: 16.0%; anticonvulsants: 8.0%; cardiotropic drugs: 6.3%; antacids: 6.3%, and antiparkinsonian agent: 2.1%). Most patients (96%) were cured within a mean period of 14 weeks. The drug was discontinued due to a skin rash in one patient. There were no cases of recurrence of the mycosis within a mean follow-up period of 37 weeks. CONCLUSIONS: This study suggests that 250 mg/day terbinafine is an effective and well-tolerated alternative to drug therapy of cutaneous sporotrichosis in a population in which itraconazole use is not possible.
BACKGROUND: There are a few studies on the treatment of sporotrichosis. The standard drug used is itraconazole. However, the use of itraconazole is limited by its interaction with other drugs. OBJECTIVE: To evaluate the effectiveness and safety of 250 mg terbinafine for the treatment of cutaneous sporotrichosis in patients in whom itraconazole use is not possible. METHODS: We performed a descriptive study of cutaneous sporotrichosis cases treated with 250 mg terbinafine for which itraconazole was contraindicated or resulted in severe or moderate pharmacological interactions. Sporotrichosis was diagnosed based on the isolation of S. schenckii. RESULTS: Fifty patients seen between July 2005 and September 2007 were included. Forty-five (92%) patients reported contact with a sick cat and 47 (94%) presented comorbidities (high blood pressure: 64.0%; diabetes mellitus: 30.0%; dyslipidemia: 16.7%; depression: 10.0%; migraine: 2.1%; Parkinsonís disease: 2.1%; peptic ulcer disease: 2.1%; heart failure: 2.1%, and arrhythmia: 2.1%). All patients used some medication interacting with itraconazole (psycholeptics: 36.0%; antidiabetic agents: 28.0%; hypolipemiant agents: 18.0%; calcium-channel blockers: 16.0%; anticonvulsants: 8.0%; cardiotropic drugs: 6.3%; antacids: 6.3%, and antiparkinsonian agent: 2.1%). Most patients (96%) were cured within a mean period of 14 weeks. The drug was discontinued due to a skin rash in one patient. There were no cases of recurrence of the mycosis within a mean follow-up period of 37 weeks. CONCLUSIONS: This study suggests that 250 mg/day terbinafine is an effective and well-tolerated alternative to drug therapy of cutaneous sporotrichosis in a population in which itraconazole use is not possible.
Authors: Paula Gonçalves Viana; Anna Barreto Fernandes Figueiredo; Isabella Dib Ferreira Gremião; Luisa Helena Monteiro de Miranda; Isabela Maria da Silva Antonio; Jéssica Sepulveda Boechat; Ana Caroline de Sá Machado; Manoel Marques Evangelista de Oliveira; Sandro Antonio Pereira Journal: Mycopathologia Date: 2017-12-08 Impact factor: 2.574
Authors: Glaucia Francesconi; Antonio Carlos Francesconi do Valle; Sonia Lambert Passos; Mônica Bastos de Lima Barros; Rodrigo de Almeida Paes; André Luiz Land Curi; José Liporage; Cássio Ferreira Porto; Maria Clara Gutierrez Galhardo Journal: Mycopathologia Date: 2010-11-21 Impact factor: 2.574
Authors: Rosane Orofino-Costa; Dayvison Francis Saraiva Freitas; Andréa Reis Bernardes-Engemann; Anderson Messias Rodrigues; Carolina Talhari; Claudia Elise Ferraz; John Verrinder Veasey; Leonardo Quintella; Maria Silvia Laborne Alves de Sousa; Rodrigo Vettorato; Rodrigo de Almeida-Paes; Priscila Marques de Macedo Journal: An Bras Dermatol Date: 2022-09-22 Impact factor: 2.113
Authors: Rodrigo do Carmo Silva; Dayvison Francis Saraiva Freitas; João Pedro Cabrera Pereira; Antonio Carlos Francesconi do Valle; Maria Clara Gutierrez-Galhardo; Fernando Almeida-Silva; Felipe Mauricio Soeiro Sampaio Journal: JAAD Case Rep Date: 2022-06-22